Literature DB >> 23220167

Waist-to-hip ratio, but not body mass index, is associated with an increased risk of Barrett's esophagus in white men.

Jennifer R Kramer1, Lori A Fischbach, Peter Richardson, Abeer Alsarraj, Stephanie Fitzgerald, Yasser Shaib, Neena S Abraham, Maria Velez, Rhonda Cole, Bhupinderjit Anand, Gordana Verstovsek, Massimo Rugge, Paola Parente, David Y Graham, Hashem B El-Serag.   

Abstract

BACKGROUND & AIMS: Abdominal obesity increases the risk of gastroesophageal reflux disease (GERD) and also might contribute to the development of Barrett's esophagus (BE), although results are inconsistent. We examined the effects of waist-to-hip ratio (WHR) and body mass index (BMI) on the risk of BE and investigated whether race, GERD symptoms, or hiatus hernia were involved.
METHODS: We conducted a case-control study using data from eligible patients who underwent elective esophagogastroduodenoscopy; 237 patients had BE and the other 1021 patients served as endoscopy controls. We also analyzed data and tissue samples from enrolled patients who were eligible for screening colonoscopies at a primary care clinic (colonoscopy controls, n = 479). All patients underwent esophagogastroduodenoscopy, completed a survey, and had anthropometric measurements taken. WHR was categorized as high if it was 0.9 or greater for men or 0.85 or greater for women. Data were analyzed with logistic regression.
RESULTS: There was no association between BMI and BE. However, more patients with BE had a high WHR (92.4%) than endoscopy controls (79.5%) or colonoscopy controls (84.6%) (P < .001 and P = .008, respectively). In adjusted analysis, patients with BE were 2-fold more likely to have a high WHR than endoscopy controls (odds ratio [OR], 1.93; 95% confidence interval [CI], 1.1-3.5), this association was stronger for patients with long-segment BE (OR, 2.81; 95% CI, 1.0-7.9). A high WHR was associated significantly with BE only in whites (OR, 2.5; 95% CI, 1.2-5.4), but not in blacks or Hispanics. GERD symptoms, hiatus hernia, or gastroesophageal valve flap grade could not account for the association.
CONCLUSIONS: High WHR, but not BMI, is associated with a significant increase in the risk of BE, especially long-segment BE and in whites. The association is not caused by GERD symptoms or hiatus hernia.
Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23220167      PMCID: PMC3606681          DOI: 10.1016/j.cgh.2012.11.028

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  37 in total

1.  Demographic variations in the rising incidence of esophageal adenocarcinoma in white males.

Authors:  E Bollschweiler; E Wolfgarten; C Gutschow; A H Hölscher
Journal:  Cancer       Date:  2001-08-01       Impact factor: 6.860

2.  Endoscopic grading of the gastroesophageal valve in patients with symptoms of gastroesophageal reflux disease (GERD).

Authors:  S Oberg; J H Peters; T R DeMeester; R V Lord; J Johansson; P F Crookes; C G Bremner
Journal:  Surg Endosc       Date:  1999-12       Impact factor: 4.584

3.  Use of a simple symptom questionnaire to predict Barrett's esophagus in patients with symptoms of gastroesophageal reflux.

Authors:  L B Gerson; R Edson; P W Lavori; G Triadafilopoulos
Journal:  Am J Gastroenterol       Date:  2001-07       Impact factor: 10.864

4.  Incidence of adenocarcinoma among patients with Barrett's esophagus.

Authors:  Frederik Hvid-Jensen; Lars Pedersen; Asbjørn Mohr Drewes; Henrik Toft Sørensen; Peter Funch-Jensen
Journal:  N Engl J Med       Date:  2011-10-13       Impact factor: 91.245

5.  Endoscopic evaluation of patients with dyspepsia: results from the national endoscopic data repository.

Authors:  David Lieberman; M Brian Fennerty; Cynthia D Morris; Jennifer Holub; Glenn Eisen; Amnon Sonnenberg
Journal:  Gastroenterology       Date:  2004-10       Impact factor: 22.682

6.  Prevalence of the metabolic syndrome and its components: findings from a Finnish general population sample and the Diabetes Prevention Study cohort.

Authors:  Pirjo Ilanne-Parikka; Johan G Eriksson; Jaana Lindström; Helena Hämäläinen; Sirkka Keinänen-Kiukaanniemi; Mauri Laakso; Anne Louheranta; Marjo Mannelin; Merja Rastas; Virpi Salminen; Sirkka Aunola; Jouko Sundvall; Timo Valle; Jorma Lahtela; Matti Uusitupa; Jaakko Tuomilehto
Journal:  Diabetes Care       Date:  2004-09       Impact factor: 19.112

7.  Risk factors for the severity of erosive esophagitis in Helicobacter pylori-negative patients with gastroesophageal reflux disease.

Authors:  H B El-Serag; J F Johanson
Journal:  Scand J Gastroenterol       Date:  2002-08       Impact factor: 2.423

8.  Gastroesophageal reflux among different racial groups in the United States.

Authors:  Hashem B El-Serag; Nancy J Petersen; Junaia Carter; David Y Graham; Peter Richardson; Robert M Genta; Linda Rabeneck
Journal:  Gastroenterology       Date:  2004-06       Impact factor: 22.682

9.  Serum immunoreactive-leptin concentrations in normal-weight and obese humans.

Authors:  R V Considine; M K Sinha; M L Heiman; A Kriauciunas; T W Stephens; M R Nyce; J P Ohannesian; C C Marco; L J McKee; T L Bauer
Journal:  N Engl J Med       Date:  1996-02-01       Impact factor: 91.245

10.  Relationship of overweight to hiatus hernia and reflux oesophagitis.

Authors:  G Stene-Larsen; R Weberg; I Frøyshov Larsen; O Bjørtuft; B Hoel; A Berstad
Journal:  Scand J Gastroenterol       Date:  1988-05       Impact factor: 2.423

View more
  43 in total

Review 1.  The role of obesity in oesophageal cancer development.

Authors:  Elizabeth Long; Ian L P Beales
Journal:  Therap Adv Gastroenterol       Date:  2014-11       Impact factor: 4.409

Review 2.  Endoluminal therapies for Barrett's esophagus.

Authors:  Carmen L Mueller; Lorenzo E Ferri
Journal:  Obes Surg       Date:  2016-04       Impact factor: 4.129

Review 3.  Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis.

Authors:  Siddharth Singh; Anamay N Sharma; Mohammad Hassan Murad; Navtej S Buttar; Hashem B El-Serag; David A Katzka; Prasad G Iyer
Journal:  Clin Gastroenterol Hepatol       Date:  2013-05-22       Impact factor: 11.382

4.  Circulating inflammatory cytokines and adipokines are associated with increased risk of Barrett's esophagus: a case-control study.

Authors:  Jose M Garcia; Andres E Splenser; Jennifer Kramer; Abeer Alsarraj; Stephanie Fitzgerald; David Ramsey; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2013-08-15       Impact factor: 11.382

5.  Is gastroesophageal reflux disease in south Indian population influenced by waist hip ratio and body mass index?

Authors:  Mala Mahalakshmi; K Arunkumar; Guru Trikudanathan; M Srinivas; S Vijaya; V Jayanthi
Journal:  Indian J Gastroenterol       Date:  2015-07

6.  Adiponectin May Modify the Risk of Barrett's Esophagus in Patients With Gastroesophageal Reflux Disease.

Authors:  Lucy M Almers; James E Graham; Peter J Havel; Douglas A Corley
Journal:  Clin Gastroenterol Hepatol       Date:  2015-01-26       Impact factor: 11.382

7.  No significant effects of smoking or alcohol consumption on risk of Barrett's esophagus.

Authors:  Aaron P Thrift; Jennifer R Kramer; Peter A Richardson; Hashem B El-Serag
Journal:  Dig Dis Sci       Date:  2013-10-11       Impact factor: 3.199

8.  Personal and family history of cancer and the risk of Barrett's esophagus in men.

Authors:  N Khalaf; D Ramsey; J R Kramer; H B El-Serag
Journal:  Dis Esophagus       Date:  2014-02-17       Impact factor: 3.429

9.  Premature Birth and Large for Gestational Age Are Associated with Risk of Barrett's Esophagus in Adults.

Authors:  Seiji Shiota; Hashem B El-Serag; Aaron P Thrift
Journal:  Dig Dis Sci       Date:  2015-11-26       Impact factor: 3.199

Review 10.  Contribution of immunomodulators to gastroesophageal reflux disease and its complications: stromal cells, interleukin 4, and adiponectin.

Authors:  Jing Li; Xiaoxin Luke Chen; Anisa Shaker; Tadayuki Oshima; Jing Shan; Hiroto Miwa; Cheng Feng; Jun Zhang
Journal:  Ann N Y Acad Sci       Date:  2016-07-21       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.